Biodel sinks 30% as BIOD-123 proves non-inferior to Humalog
This article was originally published in Scrip
Biodel's rapid-acting mealtime insulin BIOD-123 met the Phase II primary endpoint of non-inferiority to Humalog (lispro) in the treatment of type 1 diabetes, but the company's stock price sank 29.8% on 9 September based on data that show its product candidate may be less tolerable than Lilly's rapid-acting mealtime insulin analog.
You may also be interested in...
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.